DelveInsight’s “Dyslipidemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Dyslipidemia, historical and forecasted epidemiology as well as the Dyslipidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Highlights of the Dyslipidemia Market
The Key Companies working in the Dyslipidemia market include Xention Ltd, Novartis, GlaxoSmithKline, AstraZeneca, Abbott and many others.
The Key Therapies working in the Dyslipidemia market include Metformin, Rosuvastatin, Atorvastatin, Pravastatin, and many others.
Dyslipidemia Overview
Dyslipidemia is the imbalance of lipids such as cholesterol, low-density lipoprotein cholesterol, (LDL-C), triglycerides, and high-density lipoprotein (HDL). This condition can result from diet, tobacco exposure, or genetics and can lead to cardiovascular disease with severe complications.
Dyslipidemia Epidemiology Insights
The prevalence of dyslipidemia increases with age. In 2005-2008 an estimated 33.5% of U.S. adults older than 20 years of age had high LDL-C levels. Of these individuals with elevated LDL-C levels, only 48.1% received treatment, and 33.2% had their LDL-C controlled. The prevalence of LDL-C control seemed to be the lowest amongst individuals who were uninsured, Mexican American, or had income below the poverty level.
Click here to learn more about the Dyslipidemia Market Landscape
The Report Covers the Dyslipidemia Epidemiology Segmented by:
Dyslipidemia diagnosed cases
Total Dyslipidemia incident cases
Total Dyslipidemia prevalent cases
Dyslipidemia treatment cases
Dyslipidemia Market Outlook
The Dyslipidemia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Dyslipidemia market trends by analyzing the impact of current Dyslipidemia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Dyslipidemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Dyslipidemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Dyslipidemia market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Dyslipidemia Market
AstraZeneca
Xention Ltd
Novartis Pharmaceuticals
GlaxoSmithKline
And many others
Dyslipidemia Therapies Covered and Analyzed in the Report
GW856553
TA-8995
Rosuvastatin
Moxifloxacin
And many others
Learn more about the Key Companies and Emerging Therapies in the Dyslipidemia Market
Table of Contents
Key Insights
Dyslipidemia Introduction
Executive Summary of Dyslipidemia
Disease Background and Overview
Epidemiology and patient population
Dyslipidemia Emerging Therapies
Dyslipidemia Market Outlook
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Dyslipidemia Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services